Mumbai Tata Consultancy Services (TCS) on Thursday announced that it was chosen by Qiagen, a leading global provider of Sample to Insights solutions in life sciences and molecular diagnostics, in a multi-year deal.
Qiagen has been a client of TCS for nearly a decade for its other services.
TCS’ cloud solution experts will work with QIAGEN to design, implement and manage a cloud-first model, migrating the company’s workloads from its legacy data center to Microsoft Azure and build a new scalable digital core as a foundation for better ways of working. Additionally, it will improve operational agility and resilience, drive efficiency, reduce QIAGEN’s carbon footprint supporting its net zero goals.
Speaking to BusinessLine, Vikas Jain, Global Head, Life Sciences and Healthcare, Enterprise Growth Group, TCS said, “We have had partnership with Qiagen for close to 10 years and we have the contextual knowledge of their business. We know what are their aspirations and strategy going forward and how they want to improve the experience of the patients. We know the new business models they want to try and offerings they want to improve.”
“Over the last few months, both the companies have been discussing on how to enhance and digitise their core and make it future ready. As part of that, we are transforming their landscape on Cloud, helping them with the benefits of security and scalability. But most importantly, we want to help them launch new generation platforms using cloud native capabilities like expansion of applications and launching of products,” Jain added.
The platform TCS is working on will help improve their business models and engagement with the customers in a different manner, Jain said.
Growth in Life Sciences
Over the past four-five years, TCS has seen industry-leading growth in the Life Sciences and Healthcare vertical, currently contributing around 10 per cent to the IT services major’s overall business.
“Our growth rate has been around 18-22 per cent in the last three years for the life sciences and healthcare vertical. We have grown faster than overall TCS and have constantly been among the top sectors for TCS. It has grown from 5 per cent to 10 per cent over the last eight years,” Jain said.
Sharing the tailwinds that will enable the sector in the next two-three years, he said, “I think the technology adoption at scale is happening across the board in Life Sciences. Whether it is things like factory of the future or decentralized clinical trials, remote patient engagement or reimagined patient engagement, I think everything is requiring significant investments in technology. And that is what all pharma companies and all life science companies are continuing to make.”
“Data obviously is at the core and the heart of anything that life sciences companies do. With gene data coming in, molecular data coming in; data is only exploding. And so they want to be able to enable collaboration across the researchers and make this data accessible to them,” Jain added.
Published on
June 16, 2022
